MBX Biosciences, Inc. (NASDAQ: MBX)

Sector: Healthcare Industry: Biotechnology CIK: 0001776111
P/B 2.64
P/E -12.73
P/S 0.00
Market Cap 1.02 Bn
ROIC (Qtr) 0.19
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 623,000.00
Debt/Equity (Qtr) 0.00

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 223.12M provide 1448.86x coverage of short-term debt 154000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 400.08M provides 642.18x coverage of total debt 623000, indicating robust asset backing and low credit risk.
  • Strong operating cash flow of (77.69M) provides 63.36x coverage of SG&A expenses (1.23M), showing efficient operational cost management.
  • Short-term investments of 168.55M provide solid 20.71x coverage of other current liabilities 8.14M, indicating strong liquidity.
  • Tangible assets of 400.08M provide robust 49.15x coverage of other current liabilities 8.14M, indicating strong asset backing.

Cons

  • Investment activities of (21.08M) provide weak support for R&D spending of 634000, which is -33.24x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (77.69M) shows concerning coverage of stock compensation expenses of 7.51M, with a -10.35 ratio indicating potential earnings quality issues.
  • Free cash flow of (78.91M) provides weak coverage of capital expenditures of 1.23M, with a -64.26 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (80.50M) show weak coverage of depreciation charges of 374000, with a -215.23 ratio indicating high capital intensity and potential reinvestment needs.
  • Retained earnings of (202.41M) provide limited buffer against comprehensive income items of 154000, which is -1314.38x, indicating elevated exposure to market risks.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 2.46 12.31
EV to Cash from Ops. -12.69 23.25
EV to Debt 1,581.85 738.44
EV to EBIT -12.24 -9.16
EV to EBITDA 1,020.18 6.95
EV to Free Cash Flow [EV/FCF] -12.49 21.90
EV to Market Cap 0.96 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 2.64 22.34
Price to Earnings [P/E] -12.73 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -46.71 -27.13
Cash and Equivalents Growth (1y) % 67.93 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -45.88 -46.93
EBITDA Growth (1y) % -92.73 -1.68
EBIT Growth (1y) % -45.88 -56.45
EBT Growth (1y) % -45.88 -12.70
EPS Growth (1y) % 123.04 -28.31
FCF Growth (1y) % -55.87 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 18.50 3.85
Current Ratio 32.96 7.27
Debt to Equity Ratio 0.00 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22